The global pet cancer therapeutics market is projected to rise by USD 251.0 million by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 8.8 percent during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global pet cancer therapeutics market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the pet cancer therapeutics industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the therapy, type, application, and region. The global market for pet cancer therapeutics can be segmented by therapy: chemotherapy, radiation therapy, immunotherapy, targeted therapy, others. The targeted therapy segment held the largest revenue share in 2021. Pet cancer therapeutics market is further segmented by type: dog, cat, others. Among these, the dog segment was accounted for the highest revenue generator in 2021. Based on application, the pet cancer therapeutics market is segmented into: lymphoma, mast cell cancer, melanoma, others. The mast cell cancer segment captured the largest share of the market in 2021. On the basis of region, the pet cancer therapeutics market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. According to the research, North America had the largest share in the global pet cancer therapeutics market.

Market Segmentation
By therapy: chemotherapy, radiation therapy, immunotherapy, targeted therapy, others
By type: dog, cat, others
By application: lymphoma, mast cell cancer, melanoma, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global pet cancer therapeutics market with some of the key players being AB Science SA, Boehringer Ingelheim GmbH, Dechra Pharmaceuticals plc, Elanco Animal Health Incorporated, Elekta, Karyopharm Therapeutics Inc., Oasmia Pharmaceutical AB, Virbac, Zoetis, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global pet cancer therapeutics market.
– To classify and forecast the global pet cancer therapeutics market based on therapy, type, application, region.
– To identify drivers and challenges for the global pet cancer therapeutics market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global pet cancer therapeutics market.
– To identify and analyze the profile of leading players operating in the global pet cancer therapeutics market.

Why Choose This Report
– Gain a reliable outlook of the global pet cancer therapeutics market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.